Eight patients will receive jacifusen, an experimental therapy for amyotrophic lateral sclerosis (ALS) caused by FUS gene mutations, under a joint effort from the ALS Association, Project ALS, and Columbia University’s Eleanor and Lou Gehrig ALS Center. The new clinical research program, which will be supported…

“Baby, you can drive my car …” I was reminded of that Beatles lyric last Sunday while listening to my pastor’s sermon. Titled, “Taking the Back Seat,” the sermon’s theme was about subordinating our desire for control in favor of…

Skin cells from people with amyotrophic lateral sclerosis (ALS) have altered metabolisms and increased levels of a type of cellular stress called oxidative stress, a new study shows. This may indicate new treatment targets for ALS. The study, “ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated…

Spring — the kickoff for a multitude of ALS awareness events — is just around the corner! Many are already gearing up, and this is my signal to dial up my mental resilience. It helps me support their messages while keeping a firm hold on my sense of me.

A machine learning algorithm has shown that depression and a perceived lower quality of life are significant predictors of high caregiver burden among those who care for patients with amyotrophic lateral sclerosis (ALS), a study has found. The study, “Prediction of caregiver burden in amyotrophic lateral sclerosis:…

There are differences in the way the fluid around the brain and spinal cord moves in people with amyotrophic lateral sclerosis (ALS), and understanding these could have implications for the development of future therapies, a study suggests. The study, “Non-invasive MRI quantification of cerebrospinal fluid dynamics…

A gene editing technology based on CRISPR was able to slow the progression of amyotrophic lateral sclerosis in a mouse model, a new study showed, demonstrating the approach’s potential for gene therapy in people with ALS. The study, “Treatment of a Mouse Model of ALS by…

The European Medicines Agency (EMA) granted orphan drug status to Cytokinetics‘ reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. The move follows fast track designation granted in December by the U.S. Food and Drug Administration for the same indication, and provides the…

A zebrafish model that reproduces key amyotrophic lateral sclerosis (ALS) symptoms and characteristics, including protein clumping, when exposed to blue light could aid in understanding disease mechanisms and in developing new treatments. The model was described in the study, “Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related…

Oh, how I wish living with ALS weren’t so murky: We don’t know its cause, we don’t have a cure, and we measure symptom progression by way of 12 questions. I can’t do anything about the cause or cure, but I’m up on my soapbox (the one with the…